Navigation Links
RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
Date:9/10/2009

The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Beaufort, SC (Vocus) - The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Prior to forming RiversEdge BioVentures LLC, Mr. Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies.

Recently, Mr. Dodd served as President, CEO and Chairman of BioReliance Corporation, as an equity partner with Avista Capital Partners in establishing that organization as a stand-alone company following its purchase from Invitrogen Corporation (now, Life Technology, Inc.).

In addition, Mr. Dodd served as the non-executive Chairman of Stem Cell Sciences Plc. (LSE:AIM STEM; ASX: STC), leading a strategic transformation and eventual sale of that company to Stem Cells Inc. in April, 2009. Mr. Dodd also served on the Board of Stheno Corporation, a private life sciences technology company.

From June 2000 to July 2006, Mr. Dodd served as President, CEO and Director of Serologicals Corporation (NASDAQ: SERO), until the sale of Serologicals to Millipore Corporation (NYSE: MIL) in July, 2006.

From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., and as a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. Mr. Dodd also served as Chairman of the Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with major life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories.

Mr. Dodd holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management Program.

Contacts:
Kathryn Gallagher
RiversEdge BioVentures LLC
843.576.9840

Scott Litherland
Parallax Communications Group
317.335.7898

# # #

Read the full story at http://www.prweb.com/releases/2009/09/prweb2857834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Newbridge Securities Corporation Forms BioVentures Division
3. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
4. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
5. CardioDynamics Provides 2007 Shareholder Meeting Update
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
8. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
9. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):